Moving Immunotherapy Into Early-Stage Lung Cancer. Issue 6 (November 2020)

• Record Type: Journal Article
• Authors: Linehan, Anna; Forde, Patrick M.
• Is Part Of: Cancer journal. Volume 26:Issue 6(2020)
• Publication Date: 2020-11
• Subjects: Adjuvant -- atezolizumab -- immunotherapy -- durvalumab -- early stage -- immune checkpoint blockade -- lung cancer -- neoadjuvant -- nivolumab -- NSCLC -- PD-1 -- PD-L1 -- pembrolizumab -- resectable -- sintilimab -- surgery; Cancer -- Periodicals; 616.994005
• DOI: 10.1097/PPO.0000000000000493
• Languages: English
• ISSNs: 1528-9117

Abstract

Abstract : Abstract: Blockade of the programmed cell death 1 immune inhibitory pathway has revolutionized the treatment of advanced non–small cell lung cancer and led to significant improvements in overall survival. In contrast, early-stage surgically resectable lung cancer has had few treatment advances in many years and continues to be associated with a high risk of relapse despite apparent curative resection. In this review, we discuss the many ongoing efforts to incorporate programmed cell death 1 pathway blockade into the treatment paradigm for surgically resectable lung cancer both as adjuvant and neoadjuvant therapy. We review the early-phase results from neoadjuvant clinical trials, the landscape of phase III trials that are ongoing, and look to the future of immune checkpoint blockade as a potential curative therapy for surgically resectable lung cancer.